Royalty Pharma names Greg Raskin SVP, head of academic initiatives
RPRX•Raskin's background
Raskin previously served as senior vice president, technology development at Memorial Sloan Kettering Cancer Center, leading tech transfer and startup formation.
Earlier roles include vice president at AllianceBernstein’s venture fund, biotech analyst at Baker Brothers Investments, consultant at McKinsey.
Royalty Pharma appoints new head of academic initiatives
Royalty Pharma named Greg Raskin senior vice president, head of academic initiatives, effective August 2026.
He will lead outreach with academic and non-profit institutions, overseeing the Royalty Pharma Translational Prize.
